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Abstract
The severe complications of dengue virus infections, hemor-
rhagic manifestations and shock, are more commonly observed
during secondary dengue virus infections than during primary
infections. It has been speculated that these complications are
mediated by cross-reactive host-immune responses. We have
begun to analyze human T cell responses to dengue antigens in
vitro to explain the possible role of T lymphocytes in the
pathogenesis of these complications. Dengue antigens induce
proliferative responses of PBMC from dengue antibody-posi-
tive donors, but do not induce specific proliferative responses
of PBMC from dengue antibody-negative donors. IFNy is de-
tected in the culture fluids of dengue-immune PBMC stimu-
lated with dengue antigens. The cells that proliferate in the
dengue antigen-stimulated bulk cultures have CD3+, CD4+,
CD8-, CD16-, and CD20- phenotypes. Dengue-specific T
cell lines were established using limiting dilution techniques.
They have CD3+, CD4+, and CD8- phenotypes, and produce
IFNy in response to dengue antigens. Culture fluids from den-
gue-immune PBMC stimulated with dengue antigens, which
contain IFN'y, augment dengue virus infection of human mono-
cytes by dengue virus-antibody complexes.
These results indicate that PBMC from dengue-immune
donors contain CD4+ T cells that proliferate and produce
IFNy after stimulation with dengue antigens, and suggest that
the IFNy that is produced by these stimulated dengue-specific
T cells may contribute to the pathogenesis of dengue hemor-
rhagic fever and dengue shock syndrome by increasing the
number of dengue virus-infected monocytes in the presence of
cross-reactive anti-dengue antibodies.
Introduction
The severe complications of dengue virus infections, hemor-
rhagic manifestations and shock, are much more commonly
observed during secondary infections with a heterologous se-
rotype of dengue virus than during primary infections (1). It
Address reprint requests to Dr. Francis A. Ennis, Division of Infectious
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has been speculated that dengue hemorrhagic fever (DHF)'
and dengue shock syndrome (DSS) may be mediated by cross-
reactive host-immune responses (2). Halstead et al. have re-
ported that anti-dengue antibodies at subneutralizing concen-
trations enhance dengue virus infection ofFc receptor-positive
cells (3, 4). They have hypothesized that the number ofdengue
virus-infected monocytes increases in secondary infections
because of the presence of anti-dengue antibodies and this
results in DHF and DSS (1).
We recently reported that IFNy augments dengue virus
infection of human monocytes and a human monocytic cell
line, U937 (5). This augmentation required the presence of
anti-dengue antibody, and the augmentation of infection was
significantly correlated with the increased expression of Fcy
receptors induced by IFNy. We reported earlier that PBMC
from influenza-immune donors produce high titers of IFNy
when stimulated with influenza virus in vitro (6). These two
observations stimulated us to consider further the role of den-
gue-specific T cells in the pathogenesis of dengue virus infec-
tions. In this paper we describe human T cell proliferative
responses and IFNy production in vitro induced by dengue
antigens. PBMC from dengue antibody-positive donors pro-
liferate and produce IFNy after stimulation with dengue anti-
gens. The responding cells are T cells (CD3+) with CD4
(helper/inducer) phenotype. The IFNy produced augments
dengue virus infection of human monocytes by dengue virus-
antibody complexes.
Methods
Human PBMC. Peripheral blood specimens were obtained from
healthy adult Thai Red Cross blood bank donors in Bangkok, Thai-
land, and from two American donors who were known to have been
infected with dengue virus. The sera ofthese donors contained hemag-
glutination-inhibiting (HAI) antibodies to dengue viruses (mean HAI
titers; 1:49 to dengue 1, 1:58 to dengue 2, 1:118 to dengue 3, 1:272 to
dengue 4). Most of the Thai people have antibodies to dengue viruses
by age 10 (7). The two American donors had previously been immu-
nized with yellow fever vaccine. Both were known to have been in-
fected with dengue 3 virus, strain CH53489, by virus isolation from
blood and they developed antibody responses to dengue virus. PBMC
were also obtained from healthy blood bank donors from Massachu-
setts who did not have detectable levels of antibodies to dengue virus
determined using a plaque reduction neutralization test that has been
described earlier (8). We define dengue-immune donors as dengue
antibody-positive donors, and non-immune donors as dengue anti-
1. Abbreviations used in this paper: DHF, dengue hemorrhagic fever;
DSS, dengue shock syndrome; HAI, hemagglutination-inhibiting anti-
bodies; [3H]TdR, tritiated thymidine; TW20, Tween 20.
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body-negative donors. PBMC were separated by Ficoll-Hypaque den-
sity gradient centrifugation methods (9). Cells were resuspended at the
concentration of I X 107/ml in RPMI 1640 medium containing 10%
FCS (Gibco Laboratories, Grand Island, NY) and 10% DMSO (Fisher
Scientific Co., Springfield, NJ) and were cryopreserved until use (8).
Viruses. The dengue virus strains used were type 1, the Hawaii
strain; type 2, the New Guinea C strain; type 3, the CH53489 strain,
and type 4, the 814669 strain. Dengue virus types 1 and 2 were sup-
plied by Dr. Walter E. Brandt, and type 4 was supplied by Mr. Jack
McCown ofthe Walter Reed Army Institute ofResearch. Dengue virus
type 3 was supplied by one of the authors (Dr. Bruce Innis).
Preparation of dengue antigens. Dengue antigens were prepared
using dengue virus-infected Vero cells as previously reported for
measles virus (10). Vero cells were infected with dengue virus at an
approximate multiplicity of infection of 1 plaque-forming unit/cell,
and cultured in MEM containing 2% FCS. When 50% of the mono-
layer developed cytopathic effects, the cells were removed using cell
scrapers (Costar Corp., Cambridge, MA), washed three times with PBS
at 40C, treated with 0.025% glutaraldehyde (Sigma Chemical Co., St.
Louis, MO) in PBS for 15 min at 4VC, washed again three times with
PBS, and resuspended in RPMI 1640. They were then sonicated with a
sonic dismembrator (Fisher Scientific Co., Pittsburgh, PA), and cen-
trifuged at 2,500 rpm for 10 min. The supernatant fluids were collected
and used as dengue antigens. Control antigens were prepared in a
similar manner using uninfected Vero cells. 3 ml of antigen were
obtained from 15 75-cm2 flasks (Costar Corp.) of confluent Vero cells.
Alternative antigens such as purified dengue virus or mosquito cell
(C6/36)-derived dengue antigens did not induce specific proliferative
responses.
Induction ofproliferative responses ofPBMC. 2-4 X 105 PBMC
were cultured with dengue antigens diluted at 1:30 in 0.2 ml RPMI
containing 10% human AB serum (Hazleton Research Products, Inc.,
Lenexa, KS) and 5 X lo- M 2-mercaptoethanol (Sigma Chemical Co.)
in 96-well round-bottom plates (Costar, Cambridge, MA) at 37°C for 6
days. Cells were pulsed with 1.25 1sCi oftritiated thymidine ([3H]TdR)
for 8 h before harvest. Cells were harvested using a multiharvester
(Titertek, Skatron Inc., Sterling, VA) and [3H]TdR incorporation was
counted in a liquid scintillation counter (Packard Instrument Co.,
Sterling, VA).
Maintenance ofdengue antigen-stimulated PBMC. Bulk cultures
were established using 4 X 105 PBMC cultured with dengue antigens
diluted to a final concentration of 1:30 in 0.2 ml RPMI containing 10%
human AB serum, which had been obtained from a healthy, dengue
antibody-negative blood bank donor at the University of Massachu-
setts Medical Center, in 96-well round-bottom plates for 7 d. In some
experiments, blast cells were enriched on day 7 by Ficoll-Hypaque
density gradient centrifugation. 2 X I05 blast cells were cultured with 2
X 106 y-irradiated (3,000 rad) autologous PBMC in 2 ml of medium
supplemented with 10% IL 2 (Cellular Products, Inc., Buffalo, NY) in
24-well flat-bottom plates (Costar Corp.). On day 14, blast cells were
enriched again, and restimulated as described above.
Establishment ofantigen-specific T cell lines using a limited dilu-
tion method. 4 X 105 PBMC were cultured with dengue 3 antigen at a
final concentration of 1:30 in 0.2 ml RPMI containing 10% human AB
serum in 96-well round-bottom plates for 7 d. On day 7, blast cells were
enriched by Ficoll-Hypaque density gradient centrifugation and were
cultured at concentrations of 30, 10, and 3 cells/well with y-irradiated
autologous PBMC (I X 105) in 0.2 ml RPMI containing 10% human
AB serum (University of Massachusetts Medical Center), Id(% IL 2,
and dengue 3 antigen at a final dilution of 1:30 in 96-well round-bot-
tom plates. On day 14, 0.1 ml ofmedium was removed from each well
and 0.1 ml of fresh medium with human AB serum, IL 2, and dengue
antigen was added to maintain the same final concentrations described
above. On day 21, cells in wells demonstrating growth were transferred
to 48-well flat-bottom plates (Costar Corp.) and were further cultured
with 1 X 106 y-irradiated autologous PBMC in I ml ofRPMI contain-
ing 10% human AB serum, 10% IL 2, and dengue antigen at a dilution
of 1:30.
Proliferative responses ofT cell lines. 1 X I04 T cells were cultured
with 2 X 105 y-irradiated (3,000 rad) autologous PBMC in 0.2 ml
RPMI containing 10% human AB serum and dengue 3 antigen diluted
at 1:30 in 96-well round-bottom plates at 370C for 3 d. Cells were
pulsed with 1.25 MACi [3H]TdR for 8 h before harvest. Cells were har-
vested using a multiharvester and [3H]TdR incorporation was counted
in a liquid scintillation counter.
Phenotypic analysis. Anti-Leu2 (CD8) antibody reacts with sup-
pressor/cytotoxic T cells (1 1). Anti-Leu3 (CD4) antibody reacts with
helper/inducer T cells (1 1). Anti-Leu4 (CD3) antibody reacts with pan
T cells (12). Anti-Leul 1 (CD 16) antibody reacts with natural killer
cells and neutrophils (13). Anti-B 1 (CD20) antibody reacts with B cells
(14). Anti-Leu2, Leu3, Leu4, and Leul 1 antibodies were purchased
from Becton-Dickinson & Co. (Mountain View, CA). Anti-B 1 anti-
body was purchased from Coulter Electronics, Inc. (Hialeah, FL). Cell
lines and clones were stained with MAb conjugated with fluorescein-
isothiocyanate by direct immunofluorescence methods as described
earlier (15). They were observed under a fluorescence microscope (Carl
Zeiss, Inc., Oberkochen, FRG).
Immunoassays for IFN. Sandwich-type ELISA for the estimation
of IFN activity were developed at the National Institute for Biological
Standards and Control of the United Kingdom. For IFNy determina-
tion, 50 ,l of purified rabbit polyclonal antirecombinant human IFNy
(16), diluted 1:200 in PBS, was coated on U-bottomed wells of polyvi-
nyl chloride microtiter plates (Dynatech Laboratories, Alexandria,
VA) for 2 h at 370C. Remaining sites in wells were blocked overnight
with 150 ,l of 2% BSA-PBS at 4°C. Excess antibodies and blocking
buffer were removed and wells washed four times with 0.58% Tween
20 (TW20)-PBS. After the last wash, serial dilutions of human IFNy
standard (British Standard 82/587, 3,000 IU per ampoule) or culture
fluid samples were added, 50 ,l per well, and incubated at 37°C for 1 h.
Wells were then washed four times with TW20-PBS followed by: (a)
addition of 50 M1 purified anti-human IFNy MAb, 4SB3 (17) diluted
1:100 in 2% BSA-PBS, and incubation for 1 h at 37°C; (b) washing
with TW20-PBS and addition of 50 Ml biotinylated sheep anti-mouse
immunoglobulin (Amersham International, Amersham, UK), diluted
1:500 in BSA-PBS, and incubation for 1 h at 37°C; (c) washing with
TW20-PBS incubation with 50 ul streptavidin-biotinylated horsera-
dish peroxidase complex (Amersham International), diluted 1:500 in
2% BSA-PBS and incubation for 30 min at 37°C; and (d) washing
twice with TW20-PBS and twice with 0.1 M citrate-phosphate buffer,
pH 5.0, followed by the addition of orthophenylene diamine substrate
at 1 mg/ml in the 0.1 M citrate-phosphate buffer containing 0.006%
hydrogen peroxide. Color was developed in the dark for 30 min at
room temperature and the reaction terminated by addition of 50 MA 1
M H2SO4 to each well. Optical densities were read at 450 nm in a
multiskan (Titertek, Skatron, Inc.). Levels of IFN'y in culture fluid
samples were interpolated from the IFN'y standard calibration curve.
The detection limit of the IFNy-specific ELISA was 0.5 IU/ml.
For IFNa determination, the ELISA was carried out in a manner
similar to that described above for IFN'y-specific ELISA except that the
rabbit and mouse antibodies against IFNy were replaced by IFNa-spe-
cific antibodies (18, 19). This IFNa-specific ELISA was calibrated with
the first international reference preparation for human leukocyte IFN
69/19, 5,000 IU per ampoule, and the detection limit of the assay was
10 IU/ml in this version.
Effect ofIFNproduced byPBMC stimulated by dengue antigens on
dengue virus infection. Supernatant fluids from cultures of PBMC of
dengue-immune donors that had been stimulated with dengue antigen
as described above, were diluted to contain 3 U/ml of IFNy, and
culture fluids ofthe same PBMC exposed to control antigen, which did
not contain detectable levels of IFN-y, were diluted similarly. These
fluids were then used to pretreat human monocytes for 24 h before
addition of dengue virus-antibody complexes at multiplicity of infec-
tion of 10:1. Previous experiments with recombinant human IFNy
pretreatment of monocytic cells had demonstrated that these experi-
mental conditions resulted in the production of a low percentage of
infected cells 24 h later in the dengue 2 virus control group (3/212,
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1.4%) and there was no increase in the number of infected cells after
pretreatment with IFNy; however, there were significant increases in
the percentage of infected cells after pretreatment with IFN-y and ex-
posure to dengue 2 virus-antibody complexes, (29/207, 14% of cells
were infected in the absence of IFNy, and 29 and 47%, respectively
after pretreatment with 1 or 10 U of IFNy.)
Statistical analysis. Differences between values were examined by t
test and Chi square test. Differences yielding P values of < 0.05 were
regarded as significant.
Results
Proliferative responses ofPBMCfrom dengue-immune donors
induced by dengue antigens. PBMC from a dengue antibody-
positive donor were cultured with dengue or control antigens
diluted at various concentrations, and [3H]TdR incorporation
was examined. Dengue antigens induced significant prolifera-
tive responses of PBMC, and there was a good correlation
between the level of the proliferative responses and the con-
centration of dengue antigens (Fig. 1). Control antigen did not
induce significant proliferative responses. A time course study
showed that the proliferative responses reached maximum
levels on day 6 (data not presented).
The results shown in Fig. 2 illustrate the proliferative re-
sponses of PBMC obtained from 11 Thai donors and the 2
American donors who were known to have previously been
infected with dengue virus. The PBMC from these donors
showed significant proliferative responses induced by dengue
antigens (8 out of9 with dengue 1 Ag; 10 out of 13 with dengue
2 Ag; 5 out of 7 with dengue 3 Ag; 5 out of 7 with dengue 4 Ag).
The PBMC from Massachusetts blood bank donors did not
significantly proliferate in response to dengue antigens. The
failure of PBMC of some Thai donors to respond to certain
dengue antigens may be partly because the PBMC were de-
rived from healthy adults, and dengue infections are most
common during childhood. Table I contains a summary ofthe
positive proliferative responses induced by dengue antigens
using PBMC from Thai and American donors. These results
indicate that antigens of the four dengue serotypes can induce
proliferative responses using PBMC from dengue antibody-
positive donors. Neither dengue antigens nor control antigens
induced significant proliferative responses of PBMC from
nonimmune donors.
Figure 1. Proliferative re-
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Detection ofIFNy in the culturefluids ofPBMC stimulated
with dengue antigens. We examined the culture fluids of
PBMC stimulated with dengue antigens for IFNy using ELISA
with MAb to human IFNa and y. IFNy was detected at high
titer in the culture fluids of PBMC from dengue-immune
donors stimulated with dengue antigens (P < 0.02 compared
with the amount of IFNy-detected in cultures of PBMC from
nonimmune donors), but not in the culture fluids of PBMC
stimulated with control antigen or cultured alone (Table II).
IFNa was not detected in the culture fluid of PBMC after
stimulation with dengue or control antigen (data not pre-
sented). The culture fluids of PBMC from antibody-negative
donors stimulated with dengue antigens did not contain signif-
icant titers of IFNs. These results indicate that dengue-im-
mune PBMC produce high titers of IFNy after stimulation
with dengue antigens, but do not produce IFNa. IFNy was
detected at low titers in the culture fluids ofPBMC from some
donors cultured without antigens. It has been reported that
PBMC from some normal adults produce IFNy during in vitro
culture without the addition of specific antigens (20).
Characterization ofthe lymphocytes responding to dengue
antigens. We cultured the proliferating lymphocytes with 'y-ir-
radiated autologous PBMC in the presence of dengue antigens
and IL 2 for 7 or 14 d, after the original 7 d of bulk culture
stimulation, to characterize the lymphocytes that responded to
dengue antigen. Phenotypic analyses showed that the prolifer-
ating cells were predominantly CD3+, CD4+, CD8-,
CD16-, and CD20- (Table III). Therefore, the proliferating
cells are T cells with the helper/inducer phenotype. They pro-
duced IFNy after stimulation with dengue antigens, but not
after stimulation with control antigen (Table IV).
Analysis ofresponding cells by establishing dengue-specific
T cell lines. We further characterized the T cells that respond
to dengue antigen by establishing dengue-specific T cell lines
by a limiting dilution method using lymphocytes from one
American donor who was known to have been infected with
dengue 3 virus. 14 T cell lines, which responded to dengue 3
antigen but not to control antigen, were established. Three of
these lines were further expanded. The JK3 and JKlO lines
were established from wells containing 10 blast cells. The JK1 5
line was established from a well containing 30 blast cells. The
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Table L A Summary ofProliferative Responses ofPBMCfrom Dengue-immune Donors to Dengue Antigens
Dengue-immune* Nonimmune
[3H]TdR incorporation [3HJTdR incorporation
No. of donors Stimulation index No. of donors Stimulation index
cpm cpm
Dengue 1 8 7.4 9,011 6 1.0 664
(2.8-15.7) (1,018-19,343) (0.5-2.0) (142-2,357)
Dengue 2 10 7.5 4,644 9 1.1 1,038
(2.2-19.5) (1,019-10,872) (0.6-1.4) (93-2,897)
Dengue 3 5 6.6 6,005 7 1.1 732
(2.1-9.9) (1,706-13,762) (0.7-1.9) (158-1,975)
Dengue 4 5 8.2 7,936 5 1.3 611
(2.4-21.5) (2,153-17,178) (0.8-1.8) (185-1,275)
Control Ag 11 1,046 9 783
(68-4,033) (261-2,172)
NoAg 11 630 9 529
(69-1,980) (95-1,723)
4 X 105 PBMC were cultured for 6 d with dengue or control Ag diluted at 1:30. Cells were pulsed with 1.25 jCi [3H]TdR for 8 h before harvest.
Results are presented as averages. * The responses ofPBMC of dengue-immune donors who had a stimulation index greater than two with
each of the four dengue antigens are included. The stimulation index was calculated from mean counts per minute induced by dengue Ag/
mean counts per minute induced by control Ag. Quadruplicate samples were used.
cloning efficiency was 23% with 10 cells/well, and 56% with 30
cells/well, respectively. All three lines had CD3+, CD4+, and
CD8- phenotypes (data not presented), and responded to
dengue 3 antigen, but did not respond to control antigen
(Table V). They produced IFNy after stimulation with dengue
3 antigen but did not produce IFN-y after stimulation with
control antigen (Table V). They did not produce significant
titers of IFNa.
Table II. IFN'y Production by PBMCfrom Dengue Antibody-
Positive Donors after Stimulation with Dengue Antigens
IFNy*
Dengue Dengue Dengue Dengue
1 2 3 4 Control No
Donors Ag Ag Ag Ag Ag Ag
U/ml
Dengue antibody-positive
T1 25 120 28 70 2 2
T2 42 56 51 115 14 14
T3 33 47 14 26 1 3
Al 32 43 61 38 3 3
Dengue antibody-negative
M1 8 5 8 5 5 6
M2 3 11 4 3 2 3
M3 <1 2 2 2 2 2
M4 <1I <1I <1 <1 <1 <1
4 X 101 PBMC were cultured for 6 d with dengue and control Ag diluted at
1:30. Culture fluids were examined for IFN-y by ELISA.
* The titers of IFNy induced by dengue and control antigens were compared
by t test between dengue antibody-positive and antibody-negative donors.
IFNy induced by dengue 1 Ag, P < 0.001; by dengue 2 Ag, P < 0.02; by den-
gue 3 Ag, P < 0.02; by dengue 4 Ag, P < 0.01; by control Ag, P < 0.2 (not sig-
nificant); without Ag, P > 0.2 (not significant).
Augmentation of dengue virus infection of human mono-
cytes by IFNy produced by PBMC in response to dengue anti-
gen. We tried to determine whether the culture fluids ofPBMC
stimulated with dengue antigen could augment dengue virus
infection of human monocytes. We recently reported that re-
combinant human IFNy augmented dengue virus infection of
human monocytes and monocytic cells in the presence of
anti-dengue antibody (5). Culture fluids were obtained from
dengue-immune PBMC after stimulation with dengue antigen,
and they were then diluted to contain 3 U/ml ofIFNy. Culture
Table III. Phenotypes ofShort-Term-cultured T Cell Lines
Stimulated with Dengue Antigens
Days % positive cells*
of
Donor Ag culture CD3 CD4 CD8 CD16 CD20
Al Dengue 3 14 89 84 2 2 <1
21 91 83 3 ND ND
T3 Dengue 2 14 74 46 24 ND ND
T4 Dengue 2 14 84 80 8 ND ND
4 X 105 PBMC were cultured with dengue antigens diluted at 1:30 in
0.2 ml RPMI 1640 containing 10% human AB serum in 96-well
round-bottom plates for 7 d. On day 7, blast cells were enriched by
Ficoll-Hypaque density gradient centrifugation. 2 X 105 blast cells
were cultured with 2 X 106 y-irradiated autologous PBMC in 2 ml
RPMI 1640 containing 10% human AB serum, 10% IL 2 and dengue
antigens at a final dilution of 1:30 in 24-well flat-bottom plates for 7
d, and phenotypes were examined. One cell line was restimulated
again on day 14 and phenotypes were examined on day 21.
* MAb used were anti-Leu4 Ab for CD3, anti-Leu3 Ab for CD4,
anti-Leu2 Ab for CD8, anti-Leu 1 la Ab for CD16, and anti-B1 Ab
for CD20.
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Table IV. Proliferative Responses and IFN7 Production by a Short-Term-cultured T Cell Line after Stimulation with Dengue Antigens
3H-TdR incorporation IFN
Dengue Ag
Culture
Control Ag No Ag
days Dengue Ag Control Ag No Ag IFN-y IFNa IFNy IFNa IFN-y IFNa
cpm Ur/mi
14 1,325 250 270 40 <10 <1 <10 <1 <10
21 1,290 380 432 280 <10 12 <10 10 <10
5 X 104 short-term-cultured T cells were cultured with 2.5 X 105 y-irradiated autologous PBMC in 0.2 ml RPMI 1640 containing dengue 3 Ag
or control Ag diluted at 1:30 for 3 d. Cells were pulsed with 1.25 tCi [3H]TdR for 8 h before harvest. Culture fluids were examined for IFNy
and IFNa by ELISA.
fluids of the same dengue-immune PBMC that had been ex-
posed to control antigen were similarly diluted. Human mono-
cytes were exposed to these culture fluids for 24 h. They were
then washed and infected with dengue virus-antibody com-
plexes. A similar percent of the monocytes that were cultured
without the addition of culture fluids from PBMC and that
were treated with the diluted culture fluid from dengue-im-
mune PBMC that had been exposed to control antigen became
infected and expressed dengue antigens; however, increased
number of the monocytes treated with diluted culture fluids
from dengue-immune PBMC that had been exposed to dengue
antigen and contained 3 U/ml of IFN-y had dengue viral anti-
gens (Table VI, P < 0.001 in exp. 1 and P < 0.01 in exp. 2).
This augmenting effect of dengue antigen-stimulated culture
fluid was abrogated by anti-IFN-y antibody, but not by anti-
IFNa antibody (data not presented). These results confirmed
our previous report that IFN-y augments dengue virus infec-
tion ofhuman monocytes in the presence of anti-dengue anti-
body, and suggests that dengue-specific T lymphocytes may
have an important role in the pathogenesis of secondary den-
gue virus infections by increasing the number of dengue
virus-infected monocytes via IFN7y production.
Discussion
The role of T lymphocytes in recovery from dengue virus in-
fections and in the pathogenesis of severe complications has
not been explained. In this paper, we demonstrated dengue-
specific T lymphocyte proliferative responses with PBMC of
dengue antibody-positive humans. We used fixed, sonicated
dengue virus-infected Vero cells as antigens, as previously
were reported with measles virus (10), because cell-free prepa-
rations of live dengue virus did not stimulate PBMC of den-
gue-immune donors (data not presented). Proliferative re-
sponses induced by these antigens are dengue specific, because
PBMC ofdengue antibody-positive donors respond to dengue
antigens but not to control antigen, and PBMC of antibody-
negative donors do not respond to dengue or control antigens.
Antigens of the four dengue serotypes induced generally simi-
lar levels of proliferative responses of PBMC from the Thai
adult donors. The dengue infection histories of these adult
Thai donors are not known, but they all have high levels of
antibodies to the four dengue serotypes, presumably as a result
of prior natural infections. The PBMC of an American donor,
who had been immunized with yellow fever vaccine and later
became infected with dengue 3 virus, responded best to dengue
3 antigen but also responded to dengue 1, 2, and 4 antigens to
some degree (data not presented). These results suggest that
human T cell responses to primary dengue infections include
both type-specific and serotype cross-reactive responses. Fur-
ther studies are in progress to determine the subtype specifici-
ties of human T cell responses to dengue infections.
The dengue-specific proliferating lymphocytes are T cells
with CD4 phenotype. These results were obtained using bulk
culture-stimulated PBMC and dengue-specific T cell lines. It
has been reported that CD4+ T cells can be divided into two
Table V. Proliferative Responses and IFNy Production by Dengue-Specific T Cell Lines after Stimulation with Dengue Antigens
IFN
[3H]TdR incorporation
Control Ag
cpm
514
407
471
Dengue Ag
No Ag IFNy IFNa
345 70 22
275 44 <20
206 44 <20
Control Ag
IFNy IFNa
U/mi
2 <20
4 <20
4 <20
No Ag
IFNy IFNa
<1 21
2 <20
3 <20
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Lines Dengue Ag
JK3
JK1O
JK15
6,185
1,978
3,737
1 X 104 cells were cultured with 2 X 105 y-irradiated autologous PBMC in 0.2 ml RPMI 1640 containing dengue 3 Ag or control Ag diluted at
1:30 for 3 days. Cells were pulsed with 1.25 MCi [3H]TdR for 8 h before harvest. Culture fluids were examined for IFNy and IENa by ELISA.
Table VI. Augmentation ofDengue Virus
Infection ofHuman Monocytes by IFNy Produced by PBMC
in Response to Dengue Antigen
% dengue antigen-positive cells
Treatment of monocytes* Exp. I Exp. 2
None (RPMI 1640 containing
10% FCS) 22% (64/286) 5% (15/274)
Diluted culture fluid ofPBMC
stimulated with dengue antigen 37% (99/266)§ 12% (38/325)'
Diluted culture fluid ofPBMC
stimulated with control antigen 24% (75/310)1" 5% (14/301)$
The percentage of dengue antigen-positive monocytes pretreated
with culture fluids of PBMC stimulated with dengue antigen or con-
trol antigen were compared with the percentage of dengue antigen-
positive monocytes which was not treated with culture fluid by Chi-
square test. tP > 0.7 (NS); §p < 0.001; "P < 0.5 (NS); "P < 0.01.
* Culture fluids obtained from dengue-immune PBMC after stimula-
tion with dengue antigen were diluted to contain 3 U/ml of IFN-y,
and culture fluids of the same PBMC exposed to control antigen,
which did not contain detectable levels of IFN, were diluted simi-
larly. After treatment with these fluids for 24 h, human monocytes
were infected with dengue virus or dengue virus-antibody complexes
as described in Methods. The percentage of monocytes infected with
dengue virus was determined 24 h after infection by indirect immu-
nofluorescence.
subsets, helper T cells for antibody production (21) and the
inducer of the CD8+ suppressor cells (22). It has also been
reported that virus-specific, HLA class II-restricted cytotoxic
T cell clones have the CD4 phenotype (23-25). The biological
functions of dengue-specific CD4+ T cells will be analyzed in
the future experiments. We are actively pursuing the analysis
ofdengue-induced T cell responses at the clonal level and have
detected dengue specific cytotoxicity (data not presented). Our
results, which demonstrate that CD4+ T cells respond to den-
gue-Vero antigen, do not rule out a contribution for CD8+ T
cells during dengue virus infections in vivo. It has been re-
ported that the phenotypes and functions of T cells generated
in vitro after stimulation with viral antigens may vary, de-
pending on the form of the viral antigens used to stimulate, in
the case of human cytomnegalovirus (26) and varicella zoster
virus (27). Those reports state that cell-free virus preferentially
induces the proliferation of CD4+ T cells, and that virus-in-
fected autologous fibroblasts stimulated cytotoxic T lympho-
cytes with a CD8+ phenotype (26, 27). We will examine the T
cell response at the clonal level, and use autologous cell types
as alternative antigen-presenting cells in search for CD8+ re-
sponders.
Through the application of these techniques, we hope to
define the dengue epitopes which are recognized by human T
lymphocytes. Dengue virus has three structural proteins; en-
velope protein (E), membrane protein (M), and capsid protein
(C) (28, 29). It also induces seven nonstructural proteins, NS 1,
NS2a, NS2b, NS3, NS4a, NS4b, and NS5 (28, 30). Although
the role and immunogenic properties of these 10 proteins has
not been defined, E protein is thought to contain epitopes that
induce neutralizing antibody responses (31). MAb to E protein
protect mice from lethal dengue infection (32). Recently, it has
been reported that immunization of mice with dengue 2 virus
NS 1 protein provided significant protection against lethal
challenge with dengue 2 virus (33). Identification of the epi-
topes or dengue antigens that are recognized by T cells and
may have a role in protection or in the pathogenesis of DHF
and DSS is an important area for research.
The severe complications of dengue virus infections, DHF
and DSS, are much more commonly observed during second-
ary dengue infections than during primary infections (1, 2, 34).
However, a small percentage of DHF/DSS cases is observed
during primary infections and most of these are primary in-
fections of infants between 6 and 12 mo of age born to dengue
antibody-positive mothers (1, 2). Kliks et al. recently reported
that there is a correlation between the level of maternal dengue
antibodies and occurrence of DHF/DSS of the infants during
the first year of age (35). Therefore, although we speculate that
there is a role for dengue-specific T cells in the pathogenesis of
DHF/DSS, which is much more commonly observed during
secondary infections, such specific T cell memory responses do
not explain these complications when they occur, although
much less frequently, during primary infections.
In this paper, we demonstrated that dengue-specific CD4+
T cells produce high titers of IFNy. It has been reported that
antigen-specific T cells produce IFNy after stimulation with
viral antigens (6, 36, 37). The role of IFNy produced by den-
gue-specific T lymphocytes is another important subject to be
further elucidated. IFNy has potent immunoregulatory func-
tions (38, 39). IFNy increases Fcy receptors on human mono-
cytes (40, 41). Human monocytes have been identified as cells
that support dengue virus infections (42). It has been reported
that anti-dengue antibodies at subneutralizing concentrations
augment dengue virus infection ofhuman monocytes, second-
ary to the increased uptake by monocytes of dengue virus in
the form ofdengue virus-antibody complexes via Fc receptors
(3). We recently reported that recombinant human IFNy aug-
ments dengue virus infection of human monocytes and the
human monocytic cell line U937 in the presence of anti-den-
gue antibody, and that the augmented dengue virus infection is
due to the augmented expression of Fc receptors induced by
IFN (5). In these experiments, we showed that dengue virus-
specific CD4+ T cells produce high levels of IFNy in response
to dengue antigens and that culture fluids which contain IFNy
produced by dengue-specific T cells augment dengue virus in-
fection of human monocytes in the presence of anti-dengue
antibody. T cell sensitization and IFN7y production would
occur during primary dengue infections, and the restimulation
of primed cross-reactive T cells, production of IFNy and the
presence of virus-antibody complexes in the early phases of
secondary dengue infections suggest a model for the pathogen-
esis ofDHF/DSS. Based on these observations, we hypothesize
that: IFNy is produced by dengue-specific T lymphocytes after
stimulation by dengue virus antigens, and the produced IFNy
might contribute to the pathogenesis ofDHF and DSS because
IFNy increases Fcy receptors on human monocytes and this
increases the number of dengue virus-infected monocytes in
the presence of anti-dengue antibodies during secondary den-
gue infections, and by activating macrophages to release va-
soactive compounds.
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